Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

COVID-19 can lead to pulmonary complications, including organizing pneumonia. Steroids are essential in treating post-COVID-19 organizing pneumonia. However, research on the clinical benefits of initiating steroid treatment early for this condition is limited. To investigate the steroid initiation time in its association with treatment duration and corticosteroid dose for treating post-COVID-19 organizing pneumonia, we analyzed the data of 91 patients with post-COVID-19 organizing pneumonia at Chonnam National University Hospital between October 2020 and December 2022. Patients were categorized into early and late groups based on time from COVID-19 diagnosis to steroid initiation time for organizing pneumonia. The mean time interval between COVID-19 infection and steroid initiation time for treating organizing pneumonia, was 18.4±8.6 days. Within the early treatment group (treatment initiated <18.4 days after COVID-19), which included 55 patients, the mean duration of steroid treatment was 43.1±18.3days. In contrast, the late treatment group (initiated ≥18.4 days after COVID-19), which consisted of 36 patients, had a longer mean duration of steroid treatment 59.1±22.6 days) (p<0.01). Regarding corticosteroid dosing, the early treatment group had an average dosage of 0.5±0.3 mg/kg/day, in contrast to the late group, which averaged 0.8±0.3 mg/kg/day (p<0.01). Regression analysis showed steroid initiation time significantly influenced treatment duration (β=0.80 , p<0.01) and dosage (β=0.03, p<0.01). The clinical benefits of early steroid treatment for post-COVID-19 organizing pneumonia may lie in its association with reduced steroid treatment duration and dosage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458313PMC
http://dx.doi.org/10.4068/cmj.2024.60.3.166DOI Listing

Publication Analysis

Top Keywords

organizing pneumonia
28
post-covid-19 organizing
16
steroid initiation
12
initiation time
12
treating post-covid-19
8
organizing
7
pneumonia
7
treatment
5
time
5
corticosteroid therapy
4

Similar Publications

Acute fibrinous and organizing pneumonia induced by cat scratch disease: a first case report.

Front Med (Lausanne)

August 2025

Department of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

We describe the first documented case of acute fibrinous and organizing pneumonia (AFOP) induced by cat-scratch disease (CSD). A 74-year-old female patient was admitted to the hospital with progressive dyspnea and dry cough for more than 1 month that did not respond to conventional antibiotic therapy. Physical examination revealed cat bite scars on the left index finger.

View Article and Find Full Text PDF

Objective: Interstitial lung disease (ILD) is one of the most challenging involvement of autoimmune rheumatic diseases (ARDs) and could lead to significant morbidity and mortality. In this article, a collaborative work of tertiary rheumatology and pulmonology centers describing demographic, serological, and radiological findings of patients with ARD associated with ILD (ARD-ILD) is presented. Methods: A descriptive, retrospective study, and data related to demographics, clinical, laboratory, radiologic, or histopathological findings of ILD were collected from the study participants' charts.

View Article and Find Full Text PDF

Connective tissue diseases (CTD) encompass a heterogeneous group of systemic immune-mediated disorders affecting connective tissue throughout the body. Pulmonary involvement is a common and clinically significant manifestation of CTD, with interstitial lung disease (ILD) representing a major contributor to both morbidity and mortality. Therefore, early detection of CTD-ILD is critical, and a multidisciplinary approach is paramount for both diagnosis and patient management.

View Article and Find Full Text PDF

Primary pulmonary lymphoma represents an uncommon extranodal manifestation of non-Hodgkin lymphoma, with atypical clinical and radiographic features frequently leading to diagnostic challenges. Herein, we present a rare case of a 56 years-old female who presented with recurrent pyrexia. Initial thoracic computed tomography (CT) demonstrated a mass-like consolidation in the left lower lobe with bilateral pulmonary nodules.

View Article and Find Full Text PDF

We conducted a pharmacovigilance analysis of mesalazine-related adverse events (AEs) in the realworld using the America's FAERS and Japan's JADER databases. We extracted reports of mesalazine-associated AEs from FAERS and JADER spanning the first quarter of 2004 to the third quarter of 2024. In the disproportionality analysis, we applied the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma-Poisson shrinker (MGPS) algorithms for signal detection.

View Article and Find Full Text PDF